vs
Side-by-side financial comparison of Agilent Technologies (A) and GE HealthCare (GEHC). Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $1.8B, roughly 3.2× Agilent Technologies). Agilent Technologies runs the higher net margin — 17.0% vs 10.3%, a 6.6% gap on every dollar of revenue. On growth, GE HealthCare posted the faster year-over-year revenue change (7.1% vs 7.0%). Over the past eight quarters, GE HealthCare's revenue compounded faster (10.7% CAGR vs 6.9%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
A vs GEHC — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $5.7B |
| Net Profit | $305.0M | $588.0M |
| Gross Margin | 52.6% | 39.7% |
| Operating Margin | 19.6% | 14.5% |
| Net Margin | 17.0% | 10.3% |
| Revenue YoY | 7.0% | 7.1% |
| Net Profit YoY | -4.1% | -18.4% |
| EPS (diluted) | $1.07 | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $5.7B | ||
| Q3 25 | $1.7B | $5.1B | ||
| Q2 25 | $1.7B | $5.0B | ||
| Q1 25 | $1.7B | $4.8B | ||
| Q4 24 | $1.7B | $5.3B | ||
| Q3 24 | $1.6B | $4.9B | ||
| Q2 24 | $1.6B | $4.8B |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $588.0M | ||
| Q3 25 | $336.0M | $446.0M | ||
| Q2 25 | $215.0M | $486.0M | ||
| Q1 25 | $318.0M | $564.0M | ||
| Q4 24 | $351.0M | $721.0M | ||
| Q3 24 | $282.0M | $470.0M | ||
| Q2 24 | $308.0M | $428.0M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 39.7% | ||
| Q3 25 | 51.1% | 38.7% | ||
| Q2 25 | 51.9% | 39.6% | ||
| Q1 25 | 53.5% | 42.1% | ||
| Q4 24 | 53.9% | 42.8% | ||
| Q3 24 | 54.2% | 41.7% | ||
| Q2 24 | 54.4% | 41.4% |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 14.5% | ||
| Q3 25 | 20.7% | 12.7% | ||
| Q2 25 | 18.0% | 13.1% | ||
| Q1 25 | 22.4% | 13.2% | ||
| Q4 24 | 24.0% | 15.1% | ||
| Q3 24 | 21.1% | 13.9% | ||
| Q2 24 | 23.1% | 12.6% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 10.3% | ||
| Q3 25 | 19.3% | 8.7% | ||
| Q2 25 | 12.9% | 9.7% | ||
| Q1 25 | 18.9% | 11.8% | ||
| Q4 24 | 20.6% | 13.6% | ||
| Q3 24 | 17.9% | 9.7% | ||
| Q2 24 | 19.6% | 8.8% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $1.28 | ||
| Q3 25 | $1.18 | $0.98 | ||
| Q2 25 | $0.75 | $1.06 | ||
| Q1 25 | $1.11 | $1.23 | ||
| Q4 24 | $1.23 | $1.58 | ||
| Q3 24 | $0.97 | $1.02 | ||
| Q2 24 | $1.05 | $0.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $4.5B |
| Total DebtLower is stronger | $3.0B | $10.0B |
| Stockholders' EquityBook value | $6.9B | $10.4B |
| Total Assets | $12.8B | $36.9B |
| Debt / EquityLower = less leverage | 0.44× | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $4.5B | ||
| Q3 25 | $1.5B | $4.0B | ||
| Q2 25 | $1.5B | $3.7B | ||
| Q1 25 | $1.5B | $2.5B | ||
| Q4 24 | $1.3B | $2.9B | ||
| Q3 24 | $1.8B | $3.5B | ||
| Q2 24 | $1.7B | $2.0B |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $10.0B | ||
| Q3 25 | $3.4B | $10.3B | ||
| Q2 25 | $3.3B | $10.3B | ||
| Q1 25 | $3.3B | $8.8B | ||
| Q4 24 | $3.3B | $9.0B | ||
| Q3 24 | $2.1B | $10.3B | ||
| Q2 24 | $2.1B | $9.2B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $10.4B | ||
| Q3 25 | $6.4B | $10.0B | ||
| Q2 25 | $6.1B | $9.7B | ||
| Q1 25 | $6.0B | $9.2B | ||
| Q4 24 | $5.9B | $8.4B | ||
| Q3 24 | $5.9B | $8.3B | ||
| Q2 24 | $6.2B | $7.8B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $36.9B | ||
| Q3 25 | $12.2B | $36.1B | ||
| Q2 25 | $12.2B | $35.5B | ||
| Q1 25 | $11.9B | $33.6B | ||
| Q4 24 | $11.8B | $33.1B | ||
| Q3 24 | $11.0B | $33.9B | ||
| Q2 24 | $10.9B | $31.9B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.96× | ||
| Q3 25 | 0.53× | 1.03× | ||
| Q2 25 | 0.55× | 1.06× | ||
| Q1 25 | 0.56× | 0.95× | ||
| Q4 24 | 0.57× | 1.06× | ||
| Q3 24 | 0.36× | 1.24× | ||
| Q2 24 | 0.34× | 1.18× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | — |
| Free Cash FlowOCF − Capex | $175.0M | — |
| FCF MarginFCF / Revenue | 9.7% | — |
| Capex IntensityCapex / Revenue | 5.2% | 2.4% |
| Cash ConversionOCF / Net Profit | 0.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $362.0M | — | ||
| Q2 25 | $221.0M | $94.0M | ||
| Q1 25 | $431.0M | $250.0M | ||
| Q4 24 | $481.0M | — | ||
| Q3 24 | $452.0M | — | ||
| Q2 24 | $333.0M | $-119.0M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | — | ||
| Q2 25 | $107.0M | $8.0M | ||
| Q1 25 | $334.0M | $98.0M | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | $-183.0M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 6.4% | 0.2% | ||
| Q1 25 | 19.9% | 2.1% | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | -3.8% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 2.4% | ||
| Q3 25 | 5.9% | 2.1% | ||
| Q2 25 | 6.8% | 1.7% | ||
| Q1 25 | 5.8% | 3.2% | ||
| Q4 24 | 5.5% | 1.9% | ||
| Q3 24 | 5.8% | 1.9% | ||
| Q2 24 | 6.5% | 1.3% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | 0.19× | ||
| Q1 25 | 1.36× | 0.44× | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | -0.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
